As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
BUSINESS
BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
Bristol Myers Squibb is poised to counter a wave of patent cliffs in Japan with four new products and label expansions for Opdivo (nivolumab) to double its sales in the country over the next decade, the company’s local president Steve…
To read the full story
Related Article
- Off-Year Re-Pricing Will Ruin Investment Momentum: BMS Japan Chief
December 10, 2024
- BMS Japan Has Busy Years Ahead with String of Launches towards Doubling of Sales
November 22, 2023
BUSINESS
- Lenvima/Keytruda Combo Misses OS Goal in 1st Line GI Cancer Trial
January 27, 2025
- Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib
January 27, 2025
- AstraZeneca to Drive Decarbonization by Bolstering EV Infrastructure in Japan
January 24, 2025
- MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting
January 24, 2025
- Nippon Shinyaku Gets FDA’s Rare Pediatric Disease Tag for DMD Drug
January 24, 2025
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…